HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Angelo Di Leo Selected Research

lapatinib (GW572016)

5/2015Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
1/2013The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.
8/2012Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study.
7/2012Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.
4/2010Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.
2/2010Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer.
1/2010Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.
11/2009Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
8/2009Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
12/2008Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Angelo Di Leo Research Topics

Disease

70Breast Neoplasms (Breast Cancer)
09/2015 - 01/2002
28Neoplasms (Cancer)
11/2015 - 05/2002
3Neoplasm Metastasis (Metastasis)
05/2015 - 11/2006
2Exanthema (Rash)
05/2015 - 12/2008
2Diarrhea
05/2015 - 12/2008
2Circulating Neoplastic Cells
01/2013 - 07/2012
1Disease Progression
02/2015
1Adenocarcinoma
01/2015
1Infertility (Sterility)
02/2014
1Second Primary Neoplasms (Neoplasms, Second)
01/2008
1Testicular Neoplasms (Testicular Cancer)
11/2006
1Venous Thrombosis (Deep-Vein Thrombosis)
11/2006
1Thrombosis (Thrombus)
11/2006
1Acute Kidney Injury (Acute Renal Failure)
11/2006

Drug/Important Bio-Agent (IBA)

13Estrogens (Estrogen)FDA Link
02/2015 - 12/2004
11docetaxel (Taxotere)FDA Link
08/2015 - 07/2002
11AnthracyclinesIBA
07/2015 - 05/2002
11lapatinib (GW572016)FDA Link
05/2015 - 12/2008
9Paclitaxel (Taxol)FDA LinkGeneric
08/2012 - 10/2008
8Epidermal Growth Factor Receptor (EGF Receptor)IBA
05/2015 - 12/2008
8trastuzumab (Herceptin)FDA Link
05/2015 - 01/2002
8Doxorubicin (Adriamycin)FDA LinkGeneric
03/2013 - 07/2002
7HormonesIBA
09/2015 - 02/2011
6Fluorouracil (Carac)FDA LinkGeneric
05/2015 - 05/2002
6Biological Markers (Surrogate Marker)IBA
11/2014 - 03/2008
6DNA topoisomerase II alphaIBA
10/2013 - 08/2003
6trioctyl phosphine oxide (TOPO)IBA
12/2009 - 05/2002
5taxaneIBA
07/2015 - 02/2004
5Cyclophosphamide (Cytoxan)FDA LinkGeneric
05/2015 - 05/2002
4Methotrexate (Mexate)FDA LinkGeneric
05/2015 - 05/2002
4fulvestrant (Faslodex)FDA Link
01/2014 - 10/2010
4Epirubicin (Ellence)FDA LinkGeneric
10/2013 - 05/2002
3Phenobarbital (Luminal)FDA Link
11/2015 - 01/2013
3TaxoidsIBA
05/2015 - 06/2009
3Progesterone Receptors (Progesterone Receptor)IBA
12/2013 - 12/2004
3ParaffinIBA
07/2008 - 07/2002
2Epidermal Growth Factor (EGF)IBA
02/2015 - 10/2014
2capecitabine (Xeloda)FDA Link
01/2015 - 12/2008
2DNA (Deoxyribonucleic Acid)IBA
07/2012 - 12/2007
2CytotoxinsIBA
12/2009 - 02/2004
2Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
12/2008 - 03/2007
2tau Proteins (tau Protein)IBA
07/2008 - 12/2002
2TubulinIBA
07/2008 - 12/2002
1P 11 (P-11)IBA
05/2015
1everolimusFDA Link
02/2015
1Aromatase (CYP19)IBA
02/2015
1Cyclin-Dependent Kinase 4IBA
11/2014
1Tumor Suppressor Protein p53IBA
08/2014
1Phosphotransferases (Kinase)IBA
05/2014
1anthra(1,9-cd)pyrazol-6(2H)-oneIBA
05/2014
1A 19IBA
01/2014
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
08/2013
1ProgesteroneFDA LinkGeneric
08/2013
1Proliferating Cell Nuclear Antigen (PCNA)IBA
01/2013
1Investigational DrugsIBA
07/2012
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
05/2012
1N 30IBA
05/2012
1MicroRNAs (MicroRNA)IBA
05/2012
1pegylated liposomal doxorubicinIBA
11/2011
1Type II DNA Topoisomerases (Topoisomerase II)IBA
04/2011
1Estrogen Receptor Modulators (Antiestrogen)IBA
02/2011
1Messenger RNA (mRNA)IBA
12/2008
1Formaldehyde (Formol)FDA Link
07/2008
1PlatinumIBA
12/2007
1Estrogen ReceptorsIBA
04/2007
1Nonseminomatous germ cell tumorIBA
11/2006
1Etoposide (VP 16)FDA LinkGeneric
11/2006
1BEP protocolIBA
11/2006
1Cisplatin (Platino)FDA LinkGeneric
11/2006
1Bleomycin (Blenoxane)FDA LinkGeneric
11/2006
1TamoxifenFDA LinkGeneric
12/2004
1Carbon MonoxideIBA
12/2002
1CMF-B protocolIBA
05/2002

Therapy/Procedure

18Drug Therapy (Chemotherapy)
07/2015 - 04/2002
9Adjuvant Chemotherapy
08/2015 - 10/2008
1Aftercare (After-Treatment)
01/2015
1Neoadjuvant Therapy
10/2013
1Therapeutics
01/2013
1Radiotherapy
01/2009
1Thrombolytic Therapy
11/2006